YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

Core Viewpoint - YD Bio Limited has successfully completed its business combination with Breeze Holdings Acquisition Corp, marking its entry into the public markets and positioning itself as a leader in the biotechnology sector focused on cancer detection and ophthalmologic innovations [1][3][7] Business Combination and PIPE Offering - The business combination was approved by Breeze shareholders on August 14, 2025, and YD Bio's shares will begin trading on Nasdaq under the ticker symbols "YDES" and "YDESW" starting August 29, 2025 [1][7] - The PIPE offering closed concurrently with the business combination, yielding over $11,500,000 to support YD Bio's future operations [2] Company Evolution and Leadership - YD Bio has evolved from a supplier of clinical trial drugs to an innovator in diagnostics and therapeutics, with a focus on delivering solutions that improve global health [6] - The company is led by Dr. Ethan Shen, who has over 30 years of experience in the biomedical field [4][6] Business Model and Strategic Focus - YD Bio's business model emphasizes partnerships with biopharmaceutical companies to develop commercially viable drugs and diagnostics [4] - The company holds multi-decade exclusive licensing agreements and proprietary patented technologies, providing a first-mover advantage in clinical markets [5] Core Programs and Innovations - YD Bio is developing DNA methylation-based cancer detection technology, including tests for early pancreatic cancer detection and recurrent breast cancer monitoring [8] - The company is advancing stem cell and exosome therapies for ocular diseases in collaboration with 3D Global Biotech, with clinical trials planned for 2027 [8] - YD Bio also provides clinical trial and ancillary services, supporting global pharmaceutical companies [8] Market Positioning - The completion of the business combination and PIPE offering positions YD Bio for accelerated innovation and market expansion in the fast-growing healthcare sector [3][6]